Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-666-8 | CAS number: 2855-13-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Study period:
- unknown
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Data source
Reference
- Reference Type:
- publication
- Title:
- Test chamber exposure of humans to 1,6-hexamethylene diisocyanate and isophorone diisocyanate
- Author:
- Tinnerberg H, Skarping G, Dalene M and Hagmar L
- Year:
- 1 995
- Bibliographic source:
- Int. Arch. Occup. Environ. Health 67, 367-374
- Report date:
- 1995
Materials and methods
- Type of study / information:
- Type of experience: Human inhalative exposure to the test item Isophorone diisocyanate (IPDI). Determination of the IPDI content in blood and urine (via determination of Isophorone diamine (IPDA)) and determination of urinary IPDI excretion.
- Endpoint addressed:
- basic toxicokinetics
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Human inhalative exposure to the test item Isophorone diisocyanate (IPDI). Determination of the IPDI content in blood and urine (analytical determination of the corresponding Isophorone diamine (IPDA) determined as IPDA-pentafluoropropionic anhydride) and determination of urinary IPDI excretion.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- isophorone diisocyanate (IPDI)
- IUPAC Name:
- isophorone diisocyanate (IPDI)
- Reference substance name:
- 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate
- EC Number:
- 223-861-6
- EC Name:
- 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate
- Cas Number:
- 4098-71-9
- Molecular formula:
- C12H18N2O2
- IUPAC Name:
- 5-Isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane
- Details on test material:
- Isophorone diisocyanate (IPDI) was obtained from Aldrich Chemie (Steinham, Germany); purity not reported; Note: Isophorone diisocyanate (IPDI) hydrolyses rapidly and spontaneously to the corresponding amine Isophorone diamine(IPDA) after ingestion into the body.
Constituent 1
Constituent 2
Method
- Ethical approval:
- other: Study was approved by Ethics Committee at Lund University. All participants gave written informed consent.
- Details on study design:
- - Three healthy male volunteers were exposed simultaneously in a 5.6 m3 exposure chamber to concentrations of 12.1 (Tuesday),
17.7 (Thursday), and 50.7 (Saturday) ug isophorone diisocyanate/m3 for 2 hours per concentration level.
- The inhaled doses were estimated by pulmonary ventilation x exposure level x duration of exposure.
- All urine was collected for 16 days.
- Blood samples were taken before and half an hour after exposure plus daily on exposure-free days.
- Samples were hydrolyzed, i.e. conjugates were split and any residual isophorone diisocyanate was converted to isophorone diamine
(CAS No. 2855-13-2).
- This diamine was determined as its pentafluoropropionic amide by liquid chromatography / mass spectrometry. - Exposure assessment:
- estimated
- Details on exposure:
- - Three healthy male volunteers were exposed simultaneously in a 5.6 m3 exposure chamber to concentrations of 12.1 (Tuesday),
17.7 (Thursday), and 50.7 (Saturday) ug isophorone diisocyanate/m3 for 2 hours per concentration level.
- The inhaled doses were estimated by pulmonary ventilation x exposure level x duration of exposure.
Results and discussion
- Results:
- The average urinary elimination half-time was 2.8 hours. The average urinary excretion was 27 % (range 19-46%). An association
between the estimated inhaled dose and the total excreted amount was seen. The detection limit was about 0.1 µg/l in urine and < 0.1 µg/l in plasma. No isophorone diamine was found in hydrolyzed plasma. When working up samples from exposed persons without hydrolysis, no isophorone diamine was seen.
Any other information on results incl. tables
It was observed that 55%-70% of IPDI were
lost in the exposure chamber (probably due to irreversible reactions with
the walls and surfaces of the exposure chamber).
It has been implied that isophorone diisocyanate conjugates or reacts with biological molecules in the lung, which then enter the
systemic circulation. Hydrolysis releases the adducted isocyanate as amine. The analytical methods used would not distinguish
between isocyanate and amine.
Applicant's summary and conclusion
- Conclusions:
- IPDI in blood and urine could be detected indirectly as IPDA-pentafluoropropionic anhydride and urinary IPDI excretion was determined. The optimal hydrolysis condition was found giving the highest yield of IPDA in urine (hydrolysis with 3M NaOH during 4 h). The average urinary elimination half-time was 2.8 hours. The average urinary excretion was 27 % (range 19-46%). An association between the estimated inhaled dose and the total excreted amount was seen. When working up samples from exposed persons without hydrolysis, no isophorone diamine (IPDA) was seen. This means, that no free IPDA was present in the urine after exposure to IPDI. Hence, IPDA is covalently bonded in urine. No IPDA could be found in hydrolysed plasma (< ca 0.1µg/l), which could not be explained.
- Executive summary:
A method was developed to determine the test item Isophorone diisocyanate (IPDI) in blood and urine via detection of Isophorone diamine (IPDA) measured as as IPDA-pentafluoropropionic anhydride in humans exposed to IPDI by inhalation. The optimal hydrolysis condition was found giving the highest yield of IPDA in urine (hydrolysis with 3M NaOH during 4 h). The average urinary elimination half-time was 2.8 hours. The average urinary excretion was 27 % (range 19-46%). An association between the estimated inhaled dose and the total excreted amount was seen. When working up samples from exposed persons without hydrolysis, no isophorone diamine (IPDA) was seen. This means, that no free IPDA was present in the urine after exposure to IPDI. Hence, IPDA is covalently bonded in urine. No IPDA could be found in hydrolysed plasma ( ca 0.1µg/l), which could not be explained.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
